Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion (original) (raw)

• Kahn, S.E., Cooper, M.E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068–1083 (2014).
  Article CAS Google Scholar
• Demaris, K.M. & White, J.R. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 49, 289–301 (2013).
  Article CAS Google Scholar
• Jabbour, S.A. & Goldstein, B.J. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 62, 1279–1284 (2008).
  Article CAS Google Scholar
• Komoroski, B. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513–519 (2009).
  Article CAS Google Scholar
• Nair, S. & Wilding, J.P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 34–42 (2010).
  Article CAS Google Scholar
• Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509–514 (2014).
  Article CAS Google Scholar
• Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499–508 (2014).
  Article CAS Google Scholar
• Biddinger, S.B. & Kahn, C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123–158 (2006).
  Article CAS Google Scholar
• DeFronzo, R.A., Simonson, D. & Ferrannini, E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23, 313–319 (1982).
  Article CAS Google Scholar
• Campbell, P.J., Mandarino, L.J. & Gerich, J.E. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 37, 15–21 (1988).
  Article CAS Google Scholar
• Consoli, A. Role of liver in pathophysiology of NIDDM. Diabetes Care 15, 430–441 (1992).
  Article CAS Google Scholar
• Dinneen, S., Alzaid, A., Turk, D. & Rizza, R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38, 337–343 (1995).
  Article CAS Google Scholar
• Baron, A.D., Schaeffer, L., Shragg, P. & Kolterman, O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36, 274–283 (1987).
  Article CAS Google Scholar
• Unger, R.H., Aguilar-Parada, E., Muller, W.A. & Eisentraut, A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest. 49, 837–848 (1970).
  Article CAS Google Scholar
• Alford, F.P. et al. Glucagon control of fasting glucose in man. Lancet 2, 974–977 (1974).
  Article CAS Google Scholar
• Gargani, S. et al. Adaptive changes of human islets to an obesogenic environment in the mouse. Diabetologia 56, 350–358 (2013).
  Article CAS Google Scholar
• Yi, P., Park, J.S. & Melton, D.A. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell 153, 747–758 (2013).
  Article CAS Google Scholar
• Stoffel, M. & Duncan, S.A. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc. Natl. Acad. Sci. USA 94, 13209–13214 (1997).
  Article CAS Google Scholar
• Rhee, J. et al. Regulation of hepatic fasting response by PPARgamma coactivator-1α (PGC-1): requirement for hepatocyte nuclear factor 4α in gluconeogenesis. Proc. Natl. Acad. Sci. USA 100, 4012–4017 (2003).
  Article CAS Google Scholar
• Love-Gregory, L.D. et al. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4α gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes 53, 1134–1140 (2004).
  Article CAS Google Scholar
• Weedon, M.N. et al. Common variants of the hepatocyte nuclear factor-4α P2 promoter are associated with type 2 diabetes in the U.K. population. Diabetes 53, 3002–3006 (2004).
  Article CAS Google Scholar
• Han, S. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723–1729 (2008).
  Article CAS Google Scholar
• Leibiger, B. et al. Glucagon regulates its own synthesis by autocrine signaling. Proc. Natl. Acad. Sci. USA 109, 20925–20930 (2012).
  Article CAS Google Scholar
• Gylfe, E. & Gilon, P. Glucose regulation of glucagon secretion. Diabetes Res. Clin. Pract. 103, 1–10 (2014).
  Article CAS Google Scholar
• Zhang, Q. et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 18, 871–882 (2013).
  Article CAS Google Scholar
• Mueckler, M. & Thorens, B. The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 34, 121–138 (2013).
  Article CAS Google Scholar
• Fujimori, Y. et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 327, 268–276 (2008).
  Article CAS Google Scholar
• Jurczak, M.J. et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60, 890–898 (2011).
  Article CAS Google Scholar
• Kojima, N., Williams, J.M., Takahashi, T., Miyata, N. & Roman, R.J. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J. Pharmacol. Exp. Ther. 345, 464–472 (2013).
  Article CAS Google Scholar
• Powell, D.R. et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am. J. Physiol. Endocrinol. Metab. 304, E117–E130 (2013).
  Article CAS Google Scholar
• Tahara, A. et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J. Pharmacol. Sci. 120, 36–44 (2012).
  Article CAS Google Scholar
• Suzuki, M. et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J. Pharmacol. Exp. Ther. 341, 692–701 (2012).
  Article CAS Google Scholar
• Liang, Y. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 7, e30555 (2012).
  Article CAS Google Scholar
• Luippold, G., Klein, T., Mark, M. & Grempler, R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes. Metab. 14, 601–607 (2012).
  Article CAS Google Scholar
• Yamaguchi, K. et al. _In vitro_-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J. Pharmacol. Exp. Ther. 345, 52–61 (2013).
  Article CAS Google Scholar
• Devenny, J.J. et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20, 1645–1652 (2012).
  Article CAS Google Scholar
• Nagata, T. et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am. J. Physiol. Endocrinol. Metab. 304, E414–E423 (2013).
  Article CAS Google Scholar
• Cryer, P.E., Davis, S.N. & Shamoon, H. Hypoglycemia in diabetes. Diabetes Care 26, 1902–1912 (2003).
  Article CAS Google Scholar
• DeFronzo, R.A., Ferrannini, E. & Simonson, D.C. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38, 387–395 (1989).
  Article CAS Google Scholar
• Jurysta, C. et al. Glucose transport by acinar cells in rat parotid glands. Cell. Physiol. Biochem. 29, 325–330 (2012).
  Article CAS Google Scholar
• Magen, D., Sprecher, E., Zelikovic, I. & Skorecki, K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int. 67, 34–41 (2005).
  Article CAS Google Scholar
• Kerr-Conte, J. et al. Upgrading pretransplant human islet culture technology requires human serum combined with media renewal. Transplantation 89, 1154–1160 (2010).
  Article Google Scholar
• Dorrell, C. et al. Transcriptomes of the major human pancreatic cell types. Diabetologia 54, 2832–2844 (2011).
  Article CAS Google Scholar
• Lukowiak, B. et al. Identification and purification of functional human beta-cells by a new specific zinc-fluorescent probe. J. Histochem. Cytochem. 49, 519–528 (2001).
  Article CAS Google Scholar
• Schulthess, F.T. et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 9, 125–139 (2009).
  Article CAS Google Scholar
• Lefebvre, B. et al. Efficient gene delivery and silencing of mouse and human pancreatic islets. BMC Biotechnol. 10, 28 (2010).
  Article Google Scholar
• Obermeier, M. et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab. Dispos. 38, 405–414 (2010).
  Article CAS Google Scholar
• Cheng-Xue, R. et al. Tolbutamide controls glucagon release from mouse islets differently than glucose: involvement of K(ATP) channels from both alpha-cells and delta-cells. Diabetes 62, 1612–1622 (2013).
  Article Google Scholar
• Abderrahmani, A. et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 50, 1304–1314 (2007).
  Article CAS Google Scholar
• de Jonge, H.J. et al. Evidence based selection of housekeeping genes. PLoS ONE 2, e898 (2007).
  Article Google Scholar